– UK, Alderley Park – Redx Pharma plc (LON: REDX), the drug discovery and development company focused on oncology and fibrosis, today announced the appointment of Dr. Jane Griffiths to its Board of Directors as Non-Executive Chair, effective from 1 December 2021, bringing significant experience and understanding of managing global strategy across the pharmaceutical sector, together with a strong interest in sustainability and diversity.
“We are pleased to welcome Jane as Chair of the Redx Board to lead the next stage of the Company growth. She brings a wealth of pertinent global experience to the Company from her long and varied career at Johnson & Johnson, her other board positions and as a fervent champion of sustainability and diversity across business,” commented Interim Chairman, Peter Presland.
He added: “We look forward to drawing on these insights. It is a very exciting time for Redx, as we enter into Phase 2 clinical development with RXC004 as a potential treatment for Wnt-ligand driven cancers and continue to progress our Phase 1 study with RXC007 as a potential treatment for fibrotic diseases, including idiopathic pulmonary fibrosis.”
About Dr. Jane Griffiths
Dr. Jane Griffiths has enjoyed a long and successful career in the pharmaceutical sector with Johnson & Johnson. During her tenure there she held executive roles in clinical research, international and strategic marketing, product management, and operational management. In her last role before retiring in December 2019, Jane was Global Head of Actelion, where she led the integration of the Swiss biotech business following its acquisition by Johnson & Johnson. Prior to that Jane had been Company Group Chair of Janssen EMEA, the group’s research-based pharmaceutical arm. During her time with Johnson & Johnson, Jane led its Corporate Citizen Trust in EMEA and sponsored its Women’s Leadership Initiative. Jane was also a sponsor of Janssen’s Global Pharmaceuticals Sustainability Council.
Currently, Jane is a Non-Executive Director of the FTSE 100 companies, Johnson Matthey plc, BAE Systems plc, and is a member of the board of directors of TB Alliance, a not-for-profit organization dedicated to the delivery of affordable tuberculosis drugs. Jane is a past Chair of the European Federation of Pharmaceutical Industries and Associations, past Chairwoman of the PhRMA Europe Committee, and former member of the Corporate Advisory Board of the UK Government-backed ‘Your Life’ campaign, aimed at encouraging more people to study STEM subjects.
Dr. Jane Griffiths said: “I am delighted to be joining Redx at an exciting time as its programmes continue to make progress in the clinic and its research scientists look to further expand the pipeline with differentiated assets. I look forward to working closely with the Board and the management team during this next stage of growth.”
About Redx Pharma Plc
Redx Pharma is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx’s lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 program in the second half of 2021. The Company’s selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021. Initial encouraging results were reported in October 2021 and further results are expected in the first half of 2022.
The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor – pirtobrutinib/LOXO-305 – was sold to Loxo Oncology (now Eli Lilly) and is currently in several Phase 3 clinical studies, including chronic lymphocytic leukemia. In addition, Redx has forged pre-clinical asset partnerships with other blue-chip companies including AstraZeneca and Jazz Pharmaceuticals.
For more information: https://www.redxpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.